Fesko John sold $121K of NTRA
Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 302 shares of Natera, Inc. (NTRA) at an average of $400.01 ($388.20–$400.29, $0.12M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing provides fresh data on insider holdings, but the modest sale size limits market impact.
Market read
New insider sale information, modest in scale, may cause slight negative sentiment.
What to watch
The insider retains a large stake, and the sale size is tiny relative to market float.
Background
SEC Form 4 filing discloses an insider transaction by Natera's President.
Ticker impact
President John Fesko sold 302 Natera shares for $120.8K via a 10b5‑1 plan, reducing his stake to 195,276 shares.
potential slight downside pressure as the market prices the insider sell
Insider sales, even small, can be viewed as a negative signal, but the amount is modest relative to total holdings.
Market effects
Minimal impact on the broader genetic‑testing sector.
No significant regional effect.
Limited to investors tracking insider activity.
Counterpoint
The sale may be routine under a pre‑arranged plan and not reflect confidence issues.
Key entities
- CompanyNatera, Inc.
Genomics testing company listed on NASDAQ (NTRA).
- ExecutiveJohn Fesko
President and Chief Business Officer of Natera.



